It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Limitations in next-generation sequencing-based genotyping of breast cancer polygenic risk score loci

Alexandra Baumann*, Christian Ruckert*, Christoph Meier*, Tim Hutschenreiter*, Robert Remy*,
, Daviddith School⁵, Marrie Dithel^{6,} Budel Christian Nieuwerdie Ferlun⁴, Dariuch Sieuwerer ¹⁷ , Robert Remy
5. Sharman al-⁷ Benedikt Schnur", Marvin Döbel", Rudel Christian Nkouamedjo Fankep", Dariush Skowronek',
Clima Kuta¹, Nashart Awasla⁸, Awas Lang Katala⁵, Aichael Fenstar⁸ , Marvin Dobel", Rudel Christian Nkouamedjo Fankep
r Kutz¹, Norbert Arnold⁸, Anna Lena Katzko⁵, Michae Oliver Kutz1 , Norbert Arnold⁸ , Anna-Lena Katzke5 , Michael Forster8 Anna-Lena Kobiela⁴, Katharina Thiedig⁹, Andreas Zimmer¹⁰, Julia Ritter¹¹, Bernhard H.F. Anna-Lena Kobiela", Katharina Thiedig°, Andreas Zimmer"°, Julia Ritter"†, Bernhard H.F.
Mahar^{3,12}, Ellen Haniash^{13,} Karl Hashmann¹, Bisinformation Markina Green, of the Garman Weber^{3,12}, Ellen Honisch¹³, Karl Hackmann
1 , Bioinformatics Working Group of the German
 $\stackrel{*}{_{\sim}}$ \sim $\stackrel{6}{_{\sim}}$ \sim $\stackrel{6}{_{\sim}}$ \sim $\stackrel{6}{_{\sim}}$ \sim $\stackrel{6}{_{\sim}}$ Consortium for Hereditary Breast & Ovarian Cancer* , Gunnar Schmidt5 , Marc Sturm6 & Corinna $Ernst⁴$

¹Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany; ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden, Germany; National Center for Tumor Diseases Dresden (NCT/UCC), Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany; German Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Max Planck Institute of Molecular Cell

Biology and Genetics, Dresden, Germany 3 Institute of Human Genetics, University of Regensburg, Regensburg, Germany Institute of Human Genetics, Oniversity of Regensburg, Regensburg, Germany
Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany raculty, University of Cologne and University Hospital Cologne, Cologne, Germany
⁵Department of Human Genetics, Hannover Medical School (MHH), Hannover, Germa Bepartment of Human Genetics, Hannover Medical School (MHH), Humover, Germany
⁶Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen,

Tendany
Department of Human Genetics, University Medicir Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany Genetics and Functional Genomics, Oniversity of Greifswald, Greifswald, Germany
⁸Department of Gynecology and Obstetrics, Institute of Clinical Chemistry Institute of (Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany Molecular Biology, Oniversity Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Pivision of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität

München, München, Germany 10Institute for Human Genetics, Medical Center University of Freiburg, Faculty of Medicine,

University of Freiburg, Freiburg, Germany 11Department of Human Genetics, Labor Berlin – Charité Vivantes GmbH, Berlin, Germany 12 Institute of Clinical Human Genetics, University Hospital Regensburg, Regensburg, Germany

¹³Department of Gynaecology and Obstetrics, University Hospital Düsseldorf,
Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

Heinrich-Heine University Dusseldorf, Dusseldorf, Germany
A list of authors and their affiliations appears at the end of the A list of authors and their affiliations appears at the end of the paper.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

1 Abstract

2 Considering polygenic risk scores (PRSS) in individual risk prediction is increasingly becoming the standard in
2 genetic testing for hereditary breast cancer (BC). To calculate individual BC risks, the Breast and Ovaria 3 genetic testing for hereditary breast cancer (BC). To calculate individual BC risks, the Breast and Ovarian
4 Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) with inclusion of the BCAC 313 or
5 the BRIDGES 306 BC PRS is commonly used. Meaningful incorporation of PRSs relies on reproducing the allele
frequencies (AFs), and hence, the distribution of PRS values, expected by the algorithm. Here, the 324 loci of
the 5 the BRIDGES 306 BC PRS is commonly used. Meaningful incorporation of PRS relies on reproducing the allele
5 frequencies (AFs), and hence, the distribution of PRS values, expected by the algorithm. Here, the 324 loci of
5 frequencies (AFs), and hence, the distribution of PRS values, expected by the algorithm. Here, the 324 loci of
the BCAC 313 and the BRIDGES 306 BC PRS were examined in population-specific database gnomAD and in
real-world real-world data sets of five centers of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-
19 HBOC), to determine whether these expected AFs are achieved with next-generation sequencing-based
19 genotyping 8 real-world data sets of the centers of the German Consortium for Hereditary Breast and Ovarian cancer (GC-
8 HBOC), to determine whether these expected AFs are achieved with next-generation sequencing-based
8 genotyping. genotyping. Four PRS loci were non-existent in gnomAD v3.1.2 non-Finnish Europeans, further 24 loci showed
noticeably deviating AFs. In real-world data, between 16 and up to 22 loci were reported with noticeably
deviating 11 noticeably deviating AFs. In real-world data, between 16 and up to 22 loci were reported with noticeably
12 deviating AFs, and were shown to have effects on final risk prediction. Deviations depended on sequencing
13 ap noticeably deviating AFs. In real-world data, between 16 and up to 22 loci were reported with noticeably
deviating AFs, and were shown to have effects on final risk prediction. Deviations depended on sequencing
approach, v 13 approach, variant caller and calling mode (forced versus unforced) employed. Therefore, this study
14 demonstrates the necessity to apply quality assurance not only in terms of sequencing coverage but also
15 observed A 13 approach, variant caller and calling mode (forced versus unforced) employed. Therefore, this study
14 demonstrates the necessity to apply quality assurance not only in terms of sequencing coverage but also
15 observed A 15 observed AFs in a sufficiently large sample, when implementing PRSs in a routine diagnostic setting.
16 Furthermore, future PRS design should be guided by reproducibility of expected AFs in addition to the
17 observed e 15 observed AFs in a sufficiently large sample, when implementing PRSs in a routine diagnostic setting.
16 Furthermore, future PRS design should be guided by reproducibility of expected AFs in addition to the
17 observed e 16 Furthermore, future PRS design should be guided by reproducibility of expected AFs in addition to the
17 observed effect sizes.
18 Keywords: polygenic risk score, breast cancer, next-generation sequencing

18

17 observed effect sizes.
18
19 Keywords: polygenic r
20 19 Keywords: polygenic risk score, breast cancer, next-generation sequencing

20

It is made available under a CC-BY-NC-ND 4.0 International license.

21 Introduction

22 The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) is a consortium of
23 Interdisciplinary university centers specialized in providing counseling, genetic testing and healthcare for
24 Individuals 23 interdisciplinary university centers specialized in providing counseling, genetic testing and healthcare for
24 individuals at risk for familial breast and ovarian cancer (BC/OC). Clinical management of women found to b 24 individuals at risk for familial breast and ovarian cancer (BC/OC). Clinical management of women found to be
25 at increased risk for BC/OC, due to inherited pathogenic variants in established BC/OC risk genes or a stro 25 at increased risk for BC/OC, due to inherited pathogenic variants in established BC/OC risk genes or a strong
26 family history of cancer, demands for accurate and age-dependent risk estimates. Numerous studies
28 indel 27 demonstrated that the effects of BC susceptibility loci, i.e., common single nucleotide variants (SNVs) and short
28 indels, which individually contribute only slightly to individual BC risks, but whose effects can be s 27 demonstrated that the effects of BC susceptibility loci, i.e., common single nucleotide variants (SNVs) and short
28 indels, which individually contribute only slightly to individual BC risks, but whose effects can be 28 indels, which individually contribute only slightly to individual BC risks, but whose effects can be summed up
28 to polygenic risk scores (PRSs) which can achieve a clinically relevant degree of BC risk discrimination 29 to polygenic risk scores (PRSs) which can achieve a clinically relevant degree of BC risk discrimination $[1 - 3]$. As
30 the contribution of the PRS to BC risks has also been confirmed for carriers of a pathogenic vari 31 to high-penetrant BC risk genes [4 – 7], inclusion of PRSs in individual BC risk prediction is increasingly
32 becoming standard in GC-HBOC centers [8].
33 The Breast and Ovarian Analysis of Disease Incidence and Carrie

131 to high-penetrant BC risk genes [4 – 7], inclusion of PRSs in individual BC risk prediction is increasingly
32 becoming standard in GC-HBOC centers [8].
33 The Breast and Ovarian Analysis of Disease Incidence and Carri 32 becoming standard in GC-HBOC centers [0].
33 The Breast and Ovarian Analysis of Disease
34 implemented in the CE-marked CanRisk we
35 genetic germline test results, cancer family 33 The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), which is
34 Implemented in the CE-marked CanRisk web interface, provides (since v5) the straightforward inclusion of
35 g 35 genetic germline test results, cancer family history, non-genetic risk factors and PRSs in a comprehensive
36 model [9, 10]. It is therefore widely applied for individual BC risk prediction in routine diagnostics of the 35 genetic germline test results, cancer family history, non-genetic risk factors and PRSs in a comprehensive
36 model [9, 10]. It is therefore widely applied for individual BC risk prediction in routine diagnostics of the 36 model [9, 10]. It is therefore widely applied for individual BC risk prediction in routine diagnostics of the GC-
36 HBOC centers. The CanRisk web interface allows the specification of individual PRSs either as manual i 37 HBOC centers. The CanRisk web interface allows the specification of individual PRSs either as manual input
38 (including specification of the square root of the proportion of the overall polygenic variance explained) or 39 is given set of PRSs, via upload of a VCF file with the genotype or dosage information per locus to consider.
40 Whichever method is chosen, genotyping is the responsibility of the user. For PRSs for which VCF upload is 39 given set of PRSs, via upload of a VCF file with the genotype of dosage information per locus to consider.
30 Whichever method is chosen, genotyping is the responsibility of the user. For PRSs for which VCF upload is
31 41 supported, CanRisk provides specifications for incorporated loci, each including the variant (chromosome, genomic position for hg19, reference and effect allele), log odds ratio (i.e., effect size) and expected AF [11]. 41 supported, CanRisk provides specifications for incorporated loci, each including the variant (chromosome,
42 genomic position for hg19, reference and effect allele), log odds ratio (i.e., effect size) and expected AF [1 given alleles and AFs arise from high-throughput genotyping using one of two arrays, iCOGS13 or OncoArray
44 [2].
45 In the GC-HBOC centers, the BCAC 313 BC PRS, and its modified version, the BRIDGES 306 BC PRS [12], 43 given alleles and AFs arise from high-throughput genotyping using one of two arrays, iCOGS13 or OncoArray
44 [2].
45 In the GC-HBOC centers, the BCAC 313 BC PRS, and its modified version, the BRIDGES 306 BC PRS [12],
3

44 [2].
45 In t $\frac{45}{3}$ In the GC-HBOC centers, the BCAC 313 BC PRS, and its modified version, the BRIDGES 300 BC PRS $\frac{12}{12}$,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

46 are the preferred FIS variant sets employed for BC FISK prediction. The genetic germine testing and
47 are the preferred FISS variant sets employed for BC FISK prediction. The genetic germine testing and
49 are of PRS 47 genotyping of PRS loci is based on next-generation sequencing (NGS), e.g., using the TruRisk Tor further
48 specifically adapted multigene panels, whole-exome or whole-genome sequencing (WGS). The BRIDGES 306
49 BC PRS 49 BC PRS excludes loci of the original BCAC 313 BC PRS that were found not to be appropriately designable
49 BC PRS excludes loci of the original BCAC 313 BC PRS that were found not to be appropriately designable
51 of de using NGS, some of which were replaced by corresponding loci in linkage disequilibrium [12]. The assessment
of designability was mainly based on sufficient read coverage for diagnostic purposes when using a multigene
panel 50 using NGS, some of which were replaced by corresponding loci in linkage disequilibrium [12]. The assessment
51 of designability was mainly based on sufficient read coverage for diagnostic purposes when using a multigene 53 routine diagnostics and the establishment of corresponding bioinformatic workflows, further technical
54 challenges besides insufficient coverage were identified, e.g., missing variant calls or variant calling resulted Fourthermation of better approach and mapping to human reference hg19. With the implementation of bc PRS analysis in
53 routine diagnostics and the establishment of corresponding bioinformatic workflows, further technical
 53 routine diagnostics and the establishment of corresponding biomormatic workflows, further technical
54 challenges besides insufficient coverage were identified, e.g., missing variant calls or variant calling resulted in deviating alleles. Studies systematically assessing and comparing quality and pitfalls of germline genotyping
55 deviating alleles. Studies systematically assessing and comparing quality and pitfalls of germline genotyping S5 deviating alleles. Studies systematically assessing and comparing quality and pitalls or germine genotyping
56 using either arrays or NGS approaches, are rare and mainly date from the early days of the establishment of
 57 NGS in clinical diagnostics [13 – 16]. Hence, it cannot be excluded that the conclusions drawn (which were
58 also contradictory with regard to NGS or array being the more reliable and preferable approach) were based
59 58 also contradictory with regard to NGS or array being the more reliable and preferable approach) were based
59 on now predominantly outdated technologies. Nevertheless, it is well-known that accuracy of NGS tend to be
50 58 also contradictory with regard to NGS or array being the more reliable and preferable approach) were based
59 on now predominantly outdated technologies. Nevertheless, it is well-known that accuracy of NGS tend to be
5 59 on now predominantly outdated technologies. Nevertheless, it is well-known that accuracy of NGS tend to be
50 hampered in genomic regions of low complexity, i.e., homopolymer runs, tandem repeats and strongly biased
52 61 GC contents, among others $[17 - 19]$. In the Genome Aggregation Database (gnomAD), the largest and most widely used population-specific variant database, variants located in so-called low-complexity regions are flagged 61 GC contents, among others [17 – 19]. In the Genome Aggregation Database (gnomAD), the largest and most
63 Midely used population-specific variant database, variants located in so-called low-complexity regions are
64 In

63 flagged, to indicate that reported AFs may be erroneous [20, 21].
64 In this study, the Bioinformatics Working Group of the GC-HBOC conducted a systematic evaluation across
65 GC-HBOC centers to develop a detailed, locu 63 Finagged, to indicate that reported AFs may be erroneous [20, 21].
64 In this study, the Bioinformatics Working Group of the GC-HBO
65 GC-HBOC centers to develop a detailed, locus-wise assessment
66 error in NGS-based P 65 GC-HBOC centers to develop a detailed, locus-wise assessment of technical pitfalls and possible sources of
66 error in NGS-based PRS genotyping. A three-stage approach was followed. First, the AF of PRS variants were
67 66 error in NGS-based PRS genotyping. A three-stage approach was followed. First, the AF of PRS variants were
67 compared to the gnomAD AF for the European general population and it was checked if the variants can be
68 co 67 compared to the gnomAD AF for the European general population and it was checked if the variants can be
68 converted to the hg38 reference genome. Second, PRS variant AFs in real-world data sets provided by
69 participa 68 converted to the gnomab AF for the European general population and it was checked if the variants can be
69 converted to the hg38 reference genome. Second, PRS variant AFs in real-world data sets provided by
69 particip 69 participating GC-HBOC centers were compared to the AFs expected by CanRisk. Third, possible workarounds
69 participating GC-HBOC centers were compared to the AFs expected by CanRisk. Third, possible workarounds
69 for u for use in clinical diagnostics, i.e., usage of alternative alleles and proxys, were identified. The presented 4 70 For use in clinical diagnostics, i.e., usage of alternative alleles and proxys, were identified. The presented $\frac{4}{100}$

NGS-based PRS computation, especially for PRSs developed based on array data. Furthermore, the results
The underline the necessity of a comprehensive technical evaluation of PRS variant genotyping in clinical use, as
The p 22 NGS-based PRS computation, especially for PRS developed based on array data. Put incrimine, the results
23 underline the necessity of a comprehensive technical evaluation of PRS variant genotyping in clinical use, as
24 The predictive ability of an individual PRS crucially depends on the assumptions made about the underlying
The predictive ability of an individual PRS crucially depends on the assumptions made about the underlying
The SES. 74 the predictive ability of an individual PRS crucially depends on the assumptions made about the underlying
75 AFs.
77 **Materials and Methods**

76

75 AFs.
76
77 **Ma**
78 Eva 77 Materials and Methods

78 Evaluation of expected allele frequencies & convertibility to hg38

39 Two BC FRS variant sets were considered, namely of the BCAC 313 and the BRIDGES 306 BC PRS. Of the two sets, 295 loci are identical, 18 loci are unique to BCAC 313 BC PRS, and further 11 loci are unique to the BRIDGES BRIDGES 306 BC PRS, resulting in a total number of N = 324 variants to be considered. Expected AFs were
extracted from the corresponding PRS specification files at the CanRisk knowledge base [11]. Additionally, AFs
for non extracted from the corresponding PRS specification files at the CanRisk knowledge base [11]. Additionally, AFs
83 for non-Finnish Europeans (NFEs) were obtained from the gnomAD v3.1.2 database¹, which are based on
84 mor 83 for non-Finnish Europeans (NFEs) were obtained from the gnomAD v3.1.2 database¹, which are based on
84 more than 33,000 WGS samples mapped to the hg38 reference sequence. For conversion of the hg19-based
85 PRS varian for non-Finnish Europeans (NFEs) were obtained from the gnomAD v3.1.2 database², which are based on
The more than 33,000 WGS samples mapped to the hg38 reference sequence. For conversion of the hg19-based
PRS variants fr 85 PRS variants from CanRisk to hg38, the gnomAD liftover feature was used.
86 Besides AFs, gnomAD flags and warnings indicating possible technical artifacts were retrieved and recorded.
87 These included localization with Besides AFs, gnomAD flags and warnings indicating possible technical article was used.
85 Besides AFs, gnomAD flags and warnings indicating possible technical article
88 These included localization within low-complexity re Besides AFs, gnomAD flags and warnings indicating possible technical artifacts were retrieved and recorded.
87 These included localization within low-complexity regions, low-quality sites (i.e., sites that are covered in l These included localization within low-complexity regions, low-quality sites (i.e., sites that are covered in less
than 50% of considered samples [20]) and sites not passing the allele-specific GATK Variant Quality Score
R Recalibration (VQSR) filter.
89 Recalibration (VQSR) filter.
90 Determination of deviating allele frequencies

90

91 Determination of deviating allele frequencies

89 Recalibration (VQSR) filter.
90
92 To determine PRS variants 92 To determine PRS variants with considerably deviating AFs, thresholds had to be defined dependent on
93 Sample sizes and variances observed. Therefore, individual thresholds per data set were determined, using an 93 sample sizes and variances observed. Therefore, individual thresholds per data set were determined, using an
 $\frac{1}{1}$ https://gnomad.broadinstitute.org
5

 $¹$ https://gnomad.broadinstitute.org</sup>

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

descending order, and the absolute difference referring to the point with the largest Euclidean distance to the
96 imaginary line between thought points (0, 1) and (N + 1, 0), were chosen as threshold, i.e., all observed
9 95 descending order, and the absolute difference referring to the point with the largest Euclidean distance to the
96 imaginary line between thought points (0, 1) and (N + 1, 0), were chosen as threshold, i.e., all observ absolute differences greater than this threshold were determined as noticeably deviating. Corresponding
98 curves are shown in Supplementary Figures 1 to 6. If the same set of samples was processed with two
99 different va 97 absolute differences greater than this threshold were determined as noticeably deviating. Corresponding
98 curves are shown in Supplementary Figures 1 to 6. If the same set of samples was processed with two
99 different 99 different variant callers, the smaller threshold was applied in each case, to facilitate comparing variant caller
99 different variant callers, the smaller threshold was applied in each case, to facilitate comparing var 99 different variant callers, the smaller threshold was applied in each case, to facilitate comparing variant caller
00 performance.
02 **Real-world data collection**

101

102 Real-world data collection

101
102 **Real-world**
103 Genotyping re European ancestry were requested from GC-HBOC centers. Participating centers submitted observed AFs per
105 locus as well as fractions of samples that did not meet required quality criteria (e.g., with regard to minimum
10 105 Iocus as well as fractions of samples that did not meet required quality criteria (e.g., with regard to minimum
106 read depth). Furthermore, details on sequencing approaches and bioinformatic analysis workflows for PR 106 read depth). Furthermore, details on sequencing approaches and bioinformatic analysis workflows for PRS
107 genotyping were systematically recorded.
108 In total, five GC-HBOC centers provided data, namely the Institut

107 read depth). Furthermore, details on sequencing approaches and biomormatic analysis workhows for PRS
108 In total, five GC-HBOC centers provided data, namely the Institute of Medical Genetics and Applied Genomics
109 (108 In total, five GC-HBOC centers provided da
109 (IMGAG), University Hospital Tübingen, the
110 Carus Dresden, the Institute of Human Ge 109 IN total, five GC-HBOC centers provided data, namely the Institute of Medical Genetics and Applied Genetics
109 IN total, University Hospital Tübingen, the Institute for Clinical Genetics (ICG), University Hospital Car 110 Carus Dresden, the Institute of Human Genetics at the University of Münster (IHG-M), the Center for Familial
111 Breast and Ovarian Cancer (CFBOC), University Hospital Cologne, and the Institute of Human Genetics at th 111 Breast and Ovarian Cancer (CFBOC), University Hospital Cologne, and the Institute of Human Genetics at the
112 University of Regensburg (IHG-R). Each center provided two NGS-based data sets. An overview on data
113 cha 112 University of Regensburg (IHG-R). Each center provided two NGS-based data sets. An overview on data
113 characteristics is given in Table 1. A more detailed description of sample compositions, sequencing
114 approaches 2112 University of Regensburg (IHG-R). Each center provided two NGS-based data sets. An overview on data
2113 characteristics is given in Table 1. A more detailed description of sample compositions, sequencing
2114 approac 113 characteristics is given in Table 1. A more detailed description or sample compositions, sequencing
114 approaches and bioinformatic analyses can be found in Supplementary Methods.
115 **Assessment of effects of deviati** approaches and bioinformatic analyses can be found in Supplementary Methods.
115
116 **Assessment of effects of deviating allele frequencies on estimated breast cancer risks**
117 Effects of noticeably deviating AFs of PRS l

115

Assessment of effects of deviating allele frequencies on estimated breast cancer risks

 117 Effects of noticeably deviating AFs of PRS loci on CanRisk-based estimated BC risks, rely on a matricule of factors, such as the number and combination of affected loci, and additional risk factors such as results o 118 factors, such as the number and combination of affected loci, and additional risk factors such as results of

119 germline testing of established BC/OC risk genes, BC/OC ramily history, non-genetic risk factors and current
120 age. In principle, the effect of the PRS on BC risk is expected to be decreased in carriers of a pathogen 120 age. In principle, the effect of the PRS on BC risk is expected to be decreased in carriers of a pathogenic
121 germline variant in a BC risk gene with moderate or high penetrance, and furthermore, its effect is expect 121 germine variant in a BC risk gene with moderate or high penetrance, and rathermore, its effect is expected to
122 decrease with age [10]. In order to get an estimate of expected biases in predicted BC risks due to pote 122 decrease with age [10]. In order to get an estimate of expected biases in predicted bc risks due to potentially
123 erroneous PRS genotyping, estimates of 10 year and remaining lifetime risks, i.e., cumulative risks of 123 erroneous Pris genotyping, estimates of 10 year and remaining incentie risks, i.e., cumulative risks of primary
124 BC until age of 80 years, were calculated using the CanRisk web interface for imaginary cancer-unaffec 124 BC until age of 80 years, were calculated using the cannisk web interface for imaginary cancer-unaffected
125 women of three different ages, namely 20, 40, and 60 years, without any further information than (artificial

125 women of three different ages, namely 20, 40, and 60 years, without any further information than (artificial)
126 PRS.
128 using two times the expected CanRisk AF, i.e., expected dosage. For each data set, for loci sho 126 PRS.
127 To si
128 using
129 devia 127 To simulate different scenarios, artificial VCF files were constructed with an average PRS (50th percentile) by
128 using two times the expected CanRisk AF, i.e., expected dosage. For each data set, for loci showing no 129 deviating AFs, expected cannot AF, i.e., expected dosage. For each data set, for loci showing noticeably
130 deviating AFs, expected dosages were replaced by two times the observed AF in the data set. Dates of birth
13 129 deviating AFs, expected dosages were replaced by two times the observed AF in the data set. Dates of birth
130 were set to January 1 in 2003, 1983, and 1963, to simulate 20, 40, and 60 years of age at time of risk
131 130 were set to January 1 in 2003, 1383, and 1963, to simulate 20, 40, and 60 years of age at time of risk
131 computation, which were performed in October 2023, using CanRisk v2.3.5.
132 **Elaboration of workarounds**

132

133 Elaboration of workarounds

131 computation, which were performed in October 2023, using Cannisk v2.3.3.
132
134 Potential solutions for improving genotyping performance with respect to 135 Improving the calling itself) the consideration of alternative alleles or proxys. Details on the identification of
136 potential variants to substitute for this purpose are given in Supplementary Methods. Alternative v 135 improving the calling itself) the consideration of alternative alleles or proxys. Details on the identification or
136 potential variants to substitute for this purpose are given in Supplementary Methods. Alternative v 137 gnomAD v.3.1.2 with an AF matching the expected CanRisk AF, were further evaluated using the IMGAG
138 freebayes data, as this (i) was the largest data set in the study (n=1410), and (ii) the only WGS-based data set,
1 137 gnomAD v.3.1.2 with an AF matching the expected cannusk AF, were further evaluated using the IMGAG
138 freebayes data, as this (i) was the largest data set in the study (n=1410), and (ii) the only WGS-based data set,
1 138 freebayes data, as this (i) was the largest data set in the study (n=1410), and (ii) the only WGS-based data set,
139 which allowed genotyping of the entire set of putative proxys.
140 **Results**

140

141 Results

139 which allowed genotyping of the entire set of putative proxys.
140
142 Missing loci & convertibility to hg38 142 Missing loci & convertibility to hg38

It is made available under a CC-BY-NC-ND 4.0 International license.

143 For four BC PRS loci, no variants were listed at the specified genome position in ghoring v2.1.1, namely
144 rs572022984, rs113778879, rs73754909, and rs79461387. gnomAD v3.1.2 also reported no variants for three of
14 144 rs572022584, rs113778879, rs73754909, and rs75461387. gnomAD v3.1.2 also reported no variants for three or
145 these four loci for corresponding loci in hg38 as defined by dbSNP [22] (Supplementary Table 1). Locus
146

145 these four loci for corresponding foer in hg38 as defined by dbSNP [22] (Supplementary Table 1). Locus
146 rs572022984 was listed, but with an overall allele count of zero in NFE samples (Table 2).
147 For two loci, co 147 For two loci, conversion to hg38 resulted in a change in alleles, namely for rs143384623
148 C-CT; hg38: 1-145830798-C-CA) and rs550057 (hg19: 9-136146597-C-T; hg38: 9-1
149 rs143384623, the change of the alternative a 147 For two loci, conversion to higger resulted in a change in alleles, namely for rs143384623 (hig19: 1-143604302
148 C-CT; hg38: 1-145830798-C-CA) and rs550057 (hg19: 9-136146597-C-T; hg38: 9-133271182-T-C). For
150 obs

148 C-CT; hg38: 1-145830758-C-CA) and 13330037 (hg19: 9-136146357-C-T; hg38: 9-133271182-T-C). For
151 sided in gnomAD NFE samples (5142/13304 (0.39) in v2.1.1 versus 24316/64610 (0.38) in v3.1.2, two-
151 sided Fisher's 149 13143384623, the change of the alternative allele from CT to CA did not result in a noticeable shift in AFs
150 observed in gnomAD NFE samples (5142/13304 (0.39) in v2.1.1 versus 24316/64610 (0.38) in v3.1.2, two-
151

150 observed in gnomAD NFE samples (5142/13304 (0.35) in v2.1.1 versus 24316/64610 (0.36) in v3.1.2, two-
151 sided Fisher's exact test $p = 0.14$). For rs550057, the observed AFs appeared exactly opposite, i.e.,
152 3786/ 151 sided Fisher's exact test p = 0.14). For rs550057, the observed AFs appeared exactly opposite, i.e.,
152 3786/14828 (0.26) for allele T in gnomAD v2.1.1 and 49878/67552 (0.74) for allele C in gnomAD v3.1.2.
153 Theref

152 3786/14828 (0.26) for allele T in gnomAD v2.1.1 and 49878/67552 (0.74) for allele C in gnomAD v3.1.2.
153 Therefore, 1 – 49878/67552 was assumed as the gnomAD v3.1.2 effect AF at this bi-allelic site.
154 **Allele freq**

154

155 Allele frequencies & technical artifacts reported in gnomAD v3.1.2

153 Therefore, 1 − 49878797932 was assumed as the gnomAD v3.1.2 effect AF at this bi-allelic site.
154 **Allele frequencies & technical artifacts reported in gnomAD v3.1.2**
156 For 39 of the 320 PRS loci listed with AF>0 i

156 For 39 of the 320 PRS locinsted with AF>0 in gnormal v3.1.2, at least one observation of technical artifacts was
157 reported: 38 loci were flagged as being located in low complexity regions, three as being localized a 157 reported: 38 loci were magged as being located in low complexity regions, three as being localized at a low-
158 quality site, and one failed the allele-specific VQSR filter (Supplementary Table 1).
159 Due to the abso 158 quality site, and one failed the allele-specific VQSR filter (Supplementary Table 1).
169 Due to the absolute difference threshold 0.016 (Supplementary Figure 1), 24 loci v
160 deviating AFs compared to CanRisk (Figure

159 Due to the absolute difference threshold 0.016 (Supplementary Figure 1), 24 loci were determined as showing
160 deviating AFs compared to CanRisk (Figure 1, Table 2). Absolute differences ranged from 0.03 to 0.71, and

161 21 out of these 24 loci (87.5%), technical artifacts were reported in gnomAD v3.1.2.
162 **Evaluation of real-world next-generation sequencing outcome**

162

163 Evaluation of real-world next-generation sequencing outcome

162
162 **Evaluation of real-world next-generation sequencing outcome**
164 All 50 PRS loci for which a noticeably deviating AF was observed in at least one of

164 All 50 PRS loci for which a noticeably deviating AF was observed in at least one of the data sets provided by
166 Ibn five participating GC-HBOC centers are listed in Table 3.
167 (Supplementary Figure 2), resulting in 166 For the IMGAG DRAGEN data, 0.052 was calculated as 1
167 (Supplementary Figure 2), resulting in 18 loci affected (Tabl

167 (Supplementary Figure 2), resulting in 18 loci affected (Table 3, Figure 2). Of these, 16 were previously also
8 167 (Supplementary Figure 2), resulting in 18 loci affected (Table 3, Figure 2). Of these, 18 were previously also

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

169 and rs9931038. For IMGAG freebayes data, 0.036 was calculated as threshold (Supplementary Figure 2),
170 resulting in 16 loci from the BCAC 313 BC PRS determined as showing a noticeably deviating AF. Of these, 11
171 l 170 resulting in 16 loci from the BCAC 313 BC PRS determined as showing a noticeably deviating AF. Of these, 11
171 loci were also identified as showing deviating AF in IMGAG DRAGEN data, and all but rs12406858 and
172 rs1 170 resulting in 16 loci from the BCAC 313 BC PRS determined as showing a noticeably deviating AF. Of these, 11
171 loci were also identified as showing deviating AF in IMGAG DRAGEN data, and all but rs12406858 and
172 res

171 loci were also identified as showing deviating AF in IMGAG DRAGEN data, and all but rs12406858 and
172 rs11268668 were previously identified as missing or showing deviating AFs in gnomAD v3.1.2.
173 Considering genoty 173 Considering genotyping data provided by ICG, 23 of the overall 324 PRS loci did not mee
174 quality criteria (read depth ≥20) in more than 25% of samples and were discarded (Supplem
175 Additionally, GATK reported rea extral quality criteria (read depth 220) in more than 25% of samples and were discarded (Supplementary Table 2).
173 Additionally, GATK reported read depth <20 for >25% of samples for rs143384623. For 266 of the remaining
 175 Additionally, GATK reported read depth <20 for >25% of samples and were discarded (Supplementary Table 2).
175 Additionally, GATK reported read depth <20 for >25% of samples for rs143384623. For 266 of the remaining
1 176 additionally, GATK reported read depth <20 for >25% of samples for fs143384623. For 266 of the remaining
176 300 PRS loci (88.67%), forced genotyping with GATK and freebayes resulted in observation of identical AFs. Fo 177 both ICG GATK and freebayes data, 0.053 was calculated as threshold to determine noticeably deviating AFs
178 (Supplementary Figure 3). Using this threshold, 19 loci showed noticeably deviating AFs in each dataset
179 178 (Supplementary Figure 3). Using this threshold, 19 loci showed noticeably deviating AFs in each dataset
179 (including two loci exclusive for BCAC 313 BC PRS), with an overlap of 13 (Table 3, Figure 2).
180 The IHG-M p

179 (supplementary Figure 3). Using this threshold, 19 loci showed noticeably deviating AFs in each dataset
179 (including two loci exclusive for BCAC 313 BC PRS), with an overlap of 13 (Table 3, Figure 2).
180 The IHG-M p 179 (including two loci exclusive for BCAC 313 BCT RS), with an overlap of 13 (Table 3, Figure 2).
180 The IHG-M provided GATK- and DRAGEN-based BRIDGES 306 BC PRS genotyping data of 5
181 rs138179519 did not meet the qual 181 The IHS-M provided GATK- and DIMSEN-based BRIDGES 300 BC PRS genotyping data of 393 samples. Locus
181 The IHS-M provided GATK- and additionally rs774021038 using DRAGEN. Of the remaining
182 304 loci, 252 (82.89%) sho 181 13138179519 did not meet the quality criteria, and additionally rs774021098 using DRAGEN. Of the remaining
182 304 loci, 252 (82.89%) showed identical AFs (Supplementary Table 2). Using a threshold of 0.046
183 (Supple 182 304 loci, 252 (82.89%) showed identical AFs (Supplementary Table 2). Using a threshold of 0.046
183 (Supplementary Figure 4), resulted in 22 loci showing deviating AFs in GATK data, respectively 16 loci in DRAGEN
185 F

183 (Supplementary Figure 4), resulted in 22 loci showing deviating AFs in GATK data, respectively 16 loci in DRAGEN
184 data, with an overlap of 11 loci.
186 loci of the BRIDGES 306 BC PRS were considered, 243 (79.41%) of 185 For the CFBOC data based on 41
186 Ioci of the BRIDGES 306 BC PRS
187 applied (Supplementary Table 2 186 For the CFBOC data based on 416 samples, a threshold of 0.046 was calculated (Supplementary Figure 5). The
186 For the BRIDGES 306 BC PRS were considered, 243 (79.41%) of which showed identical AFs for both callers
188 187 applied (Supplementary Table 2). Overall 23 loci (all of which are included also in the BCAC 313 BC PRS)
188 showed deviating AFs: 16 loci in GATK and 17 loci in freebayes data, with an overlap of 10 loci.
189 The IHG-

187 applied (Supplementary Table 2). Overall 23 loci (all of which are included also in the BCAC 313 BC PRS)
188 showed deviating AFs: 16 loci in GATK and 17 loci in freebayes data, with an overlap of 10 loci.
189 The IHG-189 The IHG-R provided GATK- and CLC-based BRIDGES 306 BC PRS genotyping data of
190 (Supplementary Methods). Four loci did not meet the quality criteria in both settings, and
191 in the CLC setting. Of the remaining 298 l 199 The IHG-R provided GATR- and CLC-based BRIDGES 300 BC PRS genotyping data of 251 samples
190 (Supplementary Methods). Four loci did not meet the quality criteria in both settings, and additional four
191 in the CLC set 190 (Supplementary Methods). Four loci did not meet the quality criteria in both settings, and additional four
191 in the CLC setting. Of the remaining 298 loci, 228 (76.51%) showed identical AFs (Supplementary Table 2).
1 191 In the CLC setting. Of the remaining 298 loci, 228 (76.51%) showed identical AFS (Supplementary Table 2).
192 Using a threshold of 0.063 (Supplementary Figure 6), resulted in 23 loci showing noticeably deviating AFs in 192 Using a threshold of 0.063 (Supplementary Figure 6), resulted in 23 loci showing noticeably deviating AFs in GATK

193 data, respectively 19 loci in CLC data, with an overlap of 10 loci.
194 In summary, for five loci, deviating AFs were reported in all GO
195 for rs56097627, rs113778879, rs57589542, rs3988353, an
196 rs574103382, rs737 194 In summary, for the loci, deviating AFs were reported in all GC-HBOC real-world settings examined, namely
195 for rs56097627, rs113778879, rs57589542, rs3988353, and rs3057314. Further three loci, namely
196 rs57410338 195 for 13388837627, 13113778873, 1337883342, 1333888333, and 133837314. Further three loci, namely
196 rs574103382, rs73754909, and rs57920543, were reported with deviating AFs in all settings except for one
198 However,

196 rs574103302, rs73754303, and rs57320343, were reported with deviating AFs in an settings except for one
197 (Table 3).
198 However, there were also 13 loci that were conspicuous in a single setting exclusively, namely 197 (Table 3).
198 However,
199 GATK data
200 rs1447672 198 However, there were also 13 loci that were conspicuous in a single setting exclusively, namely four in IHG-R
199 GATK data (rs1511243, rs4880038, rs1027113, rs1111207), three in IHG-R CLC-data (rs10975870, rs11049431,
 199 GATK data (131311243, 134880038, 131027113, 131111207), three in IHG-IN CCC-data (1310373870, 1311043431,
199 rs144767203), two each in ICG freebayes data (rs147399132, rs199504893) and IHG-M GATK data
1902 (rs12406858 200 rs144767203), two each in ICG freebayes data (13147393152, 13153964635) and INGAG freebayes data
201 (rs143384623, rs66987842), and one each in IMGAG DRAGEN (rs9931038) and IMGAG freebayes data
202 (rs12406858). Anothe 201 (rs1243384623, rs6638642), and one each in IMGAG DRAGEN (rs3331038) and IMGAG ricebayes data
202 (rs12406858). Another 6 loci (rs34207738, rs10074269, rs55941023, rs851984, rs9421410, rs35054928) showed
204 Considering

202 (rs12406885). Another 6 loci (rs34207738, rs110074209, rss3341023, rs851304, rs9421410, rs35054320, showed
203 AF deviations in only one center, but these were concordant.
204 Considering the loci non-existent in gnomA 203 AF deviations in only one center, but these were concordant.
204 Considering the loci non-existent in gnomAD v3.1.2, rs1137
205 HBOC center, and rs73754909 only with forced DRAGEN of
206 were reported when using freeba 204 Considering the loci non-existent in gnomAD v3.1.2, rs113778879 was not observed with expected AF in any GC-
205 HBOC center, and rs73754909 only with forced DRAGEN calling in IHG-M data. For rs79461387, expected AFs
2 205 HBOC center, and 1373734909 only with forced DRAGEN calling in IHG-M data. For 1379461387, expected AFs
206 were reported when using freebayes or forced DRAGEN calling only. Of note, rs572022984 with zero allele count

207 in gnomAD v3.1.2 NFEs and an expected AF of 0.0364 in CanRisk, was consistently not observed at all or with a
208 maximum AF of 0.005 (Supplementary Table 2).
209 Five loci showing aberrant AFs in gnomAD v3.1.2 NFEs (T

207 In gnomAD v3.1.2 NFEs and an expected AF of 0.0364 in Cannusk, was consistently not observed at all or with a
208 In aximum AF of 0.005 (Supplementary Table 2).
209 In the participating GC-HBOC centers, namely rs784253

208 maximum AF of 0.005 (Supplementary Table 2).
209 Five loci showing aberrant AFs in gnomAD v3.1.2
210 the participating GC-HBOC centers, namely rs7842!
211 209 Five loci showing aberrant AFs in gnomAD v3.1.2 MFEs (Table 2) were not reported with deviating AF by any or
210 the participating GC-HBOC centers, namely rs78425380, rs62331150, rs60954078, rs10862899, and rs112855987

211

212 Implications on risk prediction

210 the participating GC-HBOC centers, namely rs78425380, rs62331150, rs60534070, rs10862859, and rs112835987.
211 **Implications on risk prediction**
213 Without further information and assuming a standardized PRS at the 50 213 Without further information and assuming a standardized PRS at the 50th percentile, the estimated 10 year
214 risks of developing primary BC of cancer-unaffected women of 20, 40, and 60 years of age were 0.1%, 1.5%,
21 214 risks of developing primary BC of cancer-unaffected women of 20, 40, and 60 years of age were 0.1%, 1.5%,
216 aberrant dosages (see Methods) ranged from 47.5% (IHG-R CLC, BRIDGES 306) up to 55.3% (ICG freebayes,
217 BC 215 and 3.4% according to Cannisk (Supplementary Table 3). Percentiles of PRSs from artificial VCF files with
216 aberrant dosages (see Methods) ranged from 47.5% (IHG-R CLC, BRIDGES 306) up to 55.3% (ICG freebayes,
217 BC 217 BCAC 313). The risk of 0.1% for a 20 year old woman was concordantly unchanged in all scenarios including
10 217 BCAC 313). The risk of 0.1% for a 20 year old woman was concordantly unchanged in all scenarios including
10

219 and for a 60 year old woman by up to 0.2% in nine scenarios.
220 Estimated remaining lifetime risks of developing primary BC assuming an average PRS (50th percentile) of
221 cancer-unaffected women aged 20, 40, and 60 219 and for a 60 year old woman by up to 0.2% in time scenarios.
220 Estimated remaining lifetime risks of developing primary BO
221 cancer-unaffected women aged 20, 40, and 60 years are
222 (Supplementary Table 3). When u 220 Estimated remaining incline risks of developing primary BC assuming an average PRS (50th percentile) or
221 cancer-unaffected women aged 20, 40, and 60 years are 11.3%, 10.9%, and 7.1% according to CanRisk
222 (Supplem 222 (Supplementary Table 3). When using PRSs from artificial VCF files with aberrant dosages, estimated lifetime
223 risks ranged from 11.1% up to 11.9% for a 20 year old woman, from 10.6% up to 11.4% for a 40 year old
224 222 (Supplementary Table 3). When using PRSS from artificial VCF files with aberrant dosages, estimated inclinit
223 risks ranged from 11.1% up to 11.9% for a 20 year old woman, from 10.6% up to 11.4% for a 40 year old
224 223 risks ranged from 11.1% up to 11.9% for a 20 year old woman, if on 10.0% up to 11.4% for a 40 year old
224 woman, and from 7.0% up to 7.4% for a 60 year old woman, whereby the lowest estimates were obtained
225 with t woman, and from 7.0% up to 7.4% for a 60 year old woman, whereby the lowest estimates were obtained
225 with the BRIDGES 306 BC PRS based on IHG-R CLC data with 19 artificial dosages imputed, and the highest
226 with the 225 with the BRIDGES 306 BC FRS based on ING R CLC data with 19 artificial dosages imputed, and the highest
226 with the BCAC 313 BC PRS based on ICG freebayes data with also 19 artificial dosages imputed.
227 **Considerati**

227

228 Consideration of alternative alleles and loci in linkage disequilibrium

226 with the BCAC 313 BCT NS based on ICG Trebayes data with also 13 artificial dosages imputed.
227
228 **Consideration of alternative alleles and loci in linkage disequilibrium**
229 For 20 PRS loci showing noticeably devi 229 For 20 FRS loci showing noticeably deviating AFS in at least one real-world NGS data set, alternative ancies or
230 overlapping variants with minimum AF 0.01 in NFEs were reported in gnomAD v3.1.2, deletions were repor 230 overlapping variants with minimum AF 0.01 in NFEs were reported in gnomAD v3.1.2 (Supplementary Table
231 4). For rs73754909 and rs79461387, both SNVs and non-existent in gnomAD v3.1.2, deletions were reported
232 with 231 4). For rs73734909 and rs79461367, both SNVs and non-existent in gnoning v3.1.2, detectors were reported
232 with comparable AFs to the ones expected by CanRisk. For both deletions, the adjacent downstream
233 nucleoti 232 with comparable AFs to the ones expected by cannosk. For both defectors, the adjacent downstream
233 nucleotide of the reference sequence was identical to the substituted nucleotide of the expected effect allele
234 (F 233 nucleotide of the reference sequence was identical to the substituted nucleotide of the expected effect allele
234 (Figure 3). For rs113778879, which is also an SNV not contained in gnomAD v3.1.2, a similar observation 234 (Figure 3). For rs113778879, which is also an SNV not contained in gnomAD v3.1.2, a similar observation
236 could be made (Supplementary Figure 7), but the reported AF exceeds the expected one by more than 0.1
236 (0.5

235 could be made (Supplementary Figure 7), but the reported AF exceeds the expected one by more than 0.1
236 (0.5762 versus 0.6818).
237 For 29 out of the 50 loci showing noticeable deviating AFs in at least one real-worl 236 (0.5762 versus 0.6810).
237 For 29 out of the 50 loci
238 GRCh37 microarray dat
239 identified (Supplementa 237 For 29 out of the 50 loci showing noticeable deviating AFs in at least one real-world data set, proxys in 1000G
238 GRCh37 microarray data, 1000G GRCh38 High Coverage WGS data, or TOPMED European data could be
239 iden 238 GRCH37 microarray data, 1000G GRCH38 High Coverage WGS data, or TOPMED European data could be
239 identified (Supplementary Table 5). For rs73754909, rs79461387, and rs113778879, LDpair based on GRCh38
240 reported the reported the same alternative alleles as gnomAD v3.1.2 (Supplementary Table 4), where the original PRS loci
240 reported the same alternative alleles as gnomAD v3.1.2 (Supplementary Table 4), where the original PRS loci
24 240 reported the same attenuative alleles as gnomAD v3.1.2 (Supplementary Table 4), where the original TRS locit
241 are non-existent.
242 Proxys and alternative alleles showing AFs in gnomAD v3.1.2 comparable to expected

241 are non-existent.
242 Proxys and altern 242 Proxys and alternative alleles showing AFs in gnomAD v3.1.2 comparable to expected CanRisk AFs, i.e., and

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

243 absolute deviation <0.016, were considered as possible workarounds for improved PRS genotyping, and
244 further evaluated with respect to observed AFs in IMGAG freebayes data (Table 4). For 20 of these 22 PRS loci,
245 244 Further evaluated with respect to observed AFs in IMGAG freebayes data (Table 4). For 20 of these 22 FRS loci,
245 absolute differences between expected and observed AFs in IMGAG freebayes data remained below the
246 p 245 absolute differences between expected and observed AFs in IMGAG freebayes data remained below the
246 previously defined IMGAG freebayes-specific threshold of 0.036. The exceptions were the substitutions of
247 rs12406 246 previously defined invided freebayes-specific threshold of 0.036. The exceptions were the substitutions of
247 rs12406858 and rs79461387. The latter is noteworthy because the original PRS locus, which is an SNV, is
248 247 rs12406858 and rs79461387. The latter is noteworthy because the original PRS locus, which is an SNV, is
248 correctly called by freebayes in forced and unforced mode (Table 3), whereas GATK HaplotypeCaller seems to
250 248 correctly called by riesbayes in forced and unforced mode (Table 3), whereas GATK Haplotypecaller seems to
249 call an overlapping deletion of sequence GAG. Also noteworthy are the potential replacements of rs73754909
 249 call an overlapping deletion of sequence GAG. Also noteworthy are the potential replacements of 1373754909
250 and rs111833376, as both variants are consistently called with noticeably deviating AFs in real-world data
 250 and rs111833376, as both variants are consistently called with noticeably deviating AFs in real-world data
251 sets.
252 **Discussion**

252

253 Discussion

 252
 253 **Dis**
 254 This s 254 This study describes the systematic evaluation of NGS-based PRS genotyping in real-world data sets of five GC-
255 HBOC centers. The observed AFs of PRS loci in individuals with European descent were employed as qualit 255 HBOC centers. The observed AFs of PRS loci in individuals with European descent were employed as quality
256 criterion, as the reproducibility of expected AFs of the PRS loci, and hence, the assumptions made about the
 256 criterion, as the reproducibility of expected AFs of the PRS loci, and hence, the assumptions made about the
257 overall PRS distribution, are an essential prerequisite for a correct risk calculation. In each setting u 257 overall FRS distribution, are all essential prerequisite for a correct risk calculation. In each setting under
258 consideration, at least 14 out of 313 BCAC BC PRS loci, respectively 306 BRIDGES BC PRS loci, showed
25 258 consideration, at least 14 out of 313 BCAC BC PRS loci, respectively 306 BRIDGES BC PRS loci, showed
259 noticeably deviating AFs. These deviations were dependent on sequencing technology, variant caller and calling
26 259 noticeably deviating AFs. These deviations were dependent on sequencing cerifiology, variant caller and calling
260 mode and can be expected to affect final BC risk calculations of the BOADICEA model implemented in Can 260 mode and can be expected to affect final BC risk calculations of the BOADICEA model implemented in Canarsk.
261 Therefore, this study demonstrates the necessity to apply quality assurance not only in terms of sequencin 262 Coverage but also in terms of observed AFs in a sufficiently large cohort, when implementing PRSs in a routine
263 diagnostic setting.
264 The presented results also point to potential solutions for improving genotypin

262 coverage but also in terms of observed AFs in a sufficiently large cohort, when implementing PRSs in a routine
263 diagnostic setting.
264 The presented results also point to potential solutions for improving genotypin 263 diagnostic setting.
264 The presented rest
265 the achievement of
266 or consideration of 264 The presented results also point to potential solutions for improving genotyping performance with respect to
266 the achievement of expected AFs for several loci, these primarily include the use of alternative variant 265 the achievement of expected AFs for several loci, these primarily include the use of alternative variant callers
266 or consideration of proxy variants. The use of certain variant callers resulted consistently in notic 267 deviating AFs, which were not observed for other callers. This concerned e.g. rs62485509 when using
12 267 deviating AFs, which were not observed for other callers. This concerned e.g. rs62485509 when using

268 DRAGEN, and rs11268668 when using rieebayes (Table 3). In each setting under investigation considering
269 identical samples, the number of loci whose AFs match the expected AFs could be increased by variant-
270 speci

270 specific selection of the variant caller.
271 Comparison to large-scale population-specific data, such as gnomAD and 1000G High Coverage WGS,
272 indicates that several PRS loci do not appear or appear with different a 270 specific selection of the variant caller.
271 Comparison to large-scale populatio
272 indicates that several PRS loci do no
273 genotyping. Here, four loci have bee 272 indicates that several PRS loci do not appear or appear with different alleles in NGS than in array-based
273 genotyping. Here, four loci have been identified for which the use of alternative alleles could lead to the
 273 genotyping. Here, four loci have been identified for which the use of alternative alleles could lead to the
274 achievement of the intended, originally array-based determined AF, if NGS-based genotyping does not do so
 273 genotyping. Here, four loci have been identified for which the use of alternative alleles could lead to the
274 achievement of the intended, originally array-based determined AF, if NGS-based genotyping does not do so
 274 achievement of the intended, originally array-based determined AF, if NGS-based genotyping does not do so
276 (Table 4). Two of these loci were absent in gnomAD v3.1.2 NFEs, which was also true for rs113778879 and
276 276 (Table 4). Two of these loci were absent in gnomAD v3.1.2 NFEs, which was also true for rs11372002384.
276 (rs572022984. As potential workaround for rs113778879, which is an SNV, an overlapping 5bp deletion was identi 276 rs372022304. As potential workaround for rs113778873, which is an SNV, an overlapping 3bp deletion was
278 dentified, but the observed AF exceeds the expected one by more than 0.1 (Supplementary Table 4).
278 gnomAD SV 278 gnomAD SV v2.1 [23] reports a 1,370bp deletion starting at the same genomic position as rs572022984,
279 namely DEL_2_27095, with an AF of 0.0417 in Europeans. However, genotyping of structural variants requires
280 ad 278 gnomAD SV v2.1 [23] reports a 1,370bp deletion starting at the same genomic position as rs372022304,
279 namely DEL_2_27095, with an AF of 0.0417 in Europeans. However, genotyping of structural variants requires
280 a 279 namely DEL_2_27055, with an AF of 0.0417 in Europeans. However, genotyping or structural variants requires
280 adapted variant calling approaches and therefore might be unfeasible within the scope of PRS genotyping in

281 but the diagnostic setting.
281 but in a more diagnostic setting.
282 but in a workarounds are available for loci showing noticeably deviating AFs, only imputation of the expected
283 dosage according to CanRisk remain 282 If no workarounds are ava
283 dosage according to Can
284 calculation or setting the 282 If no workarounds are available for loci showing noticeably deviating AFs, only imputation of the expected
283 dosage according to CanRisk remains. This leads to smaller errors than omitting the locus from PRS
284 calc 283 dosage according to CanRisk remains. This leads to smaller errors than omitting the locus from PRS,
284 calculation or setting the genotype to 0/0. However, each imputation causes a shift towards the mean PRS,
286 PRSs

284 calculation or setting the genotype to 0/0. However, each imputation causes a shift towards the mean PRS,
286 and therefore imputations are meaningful only up to a certain extent.
286 PRSs for calculating individual BC 286 PRSs for calculating individual BC risks will continue to evolve. For exa
287 aims to develop multi-ancestry PRSs. In addition, PRSs become also mother diseases with a genetic component [24,25]. The presented result PRSs for calculating individual BC risks will continue to evolve. For example, currently the Confluence Project
287 aims to develop multi-ancestry PRSs. In addition, PRSs become also more and more relevant for diagnostics 287 and the diseases with a genetic component [24,25]. The presented results underline that it would facilitate the
289 other diseases with a genetic component [24,25]. The presented results underline that it would facilit 289 implementation in clinical routine and thus also increase the reliability of genetic diagnostics if the design of
290 future PRSs would be guided by the reproducibility of the expected AFs in addition to the observed 289 Implementation in clinical routine and thus also increase the reliability of genetic diagnostics if the design of
290 future PRSs would be guided by the reproducibility of the expected AFs in addition to the observed e 290 future PRSs would be guided by the reproducibility of the expected AFs in addition to the observed effect
291 sizes. A straightforward strategy to achieve this could be to ensure comparability of AFs in large-scale
 $\$ $\frac{291}{\text{https://confluence.cancer.gov}}$ 13

 2 https://confluence.cancer.gov

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.12.15.23298835;](https://doi.org/10.1101/2023.12.15.23298835) this version posted December 17, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY-NC-ND 4.0 International license.

- 317 CHEK2 germline mutation carriers. *J Natl Cancer Inst.* 2021; 113:893–899.
318 S. Borde J, Laitman Y, Blümcke B, Niederacher D, Weber-Lassalle K, Sutter C, Rump A, Arnold N, Wang
319 Gohrke S, Horváth J, et al. Polygen
- 317 CHEKZ germline mutation carriers. J Nutr Curicer Inst. 2021, 113:893–899.
318 S. Borde J, Laitman Y, Blümcke B, Niederacher D, Weber-Lassalle K, Sutter C
319 Gohrke S, Horváth J, et al. Polygenic risk scores indicate e
-
-
- 319 5. Borde J, Latinian T, Blumcke B, Niederlacher B, Weber-Lassalle K, Sutter C, Rump A, Arnold N, Wang-
319 6ohrke S, Horváth J, et al. Polygenic risk scores indicate extreme ages at onset of breast cancer in
320 female
- Gohrke S, Horváth J, et al. Polygenic risk scores indicate extreme ages at onset of breast cancer in
320 female *BRCA1/2* pathogenic variant carriers. *BMC Cancer*. 2022; 22:1–9.
321 6. Gallagher S, Hughes E, Wagner S, Tsh 320 female BRCA1/2 pathogenic variant carriers. BMC Cancer. 2022, 22:1–9.
321 6. Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian /
322 Lancaster J, et al. Association of a polygenic risk score with
-
- 321 6. Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Bomchek SM, Garber J,
322 Lancaster J, et al. Association of a polygenic risk score with breast cancer among women carriers of
323 high-and
- 232 Lancaster J, et al. Association of a polygenic risk score with breast cancer among women carriers of
323 high-and moderate-risk breast cancer genes. JAMA Netw Open. 2020; 3:e208501-e208501.
324 7. Kuchenbaecker KB, McG 323 high-and moderate-risk breast cancer genes. JAMA Netw Open. 2020, 3:e208501–e208501.
324 7. Kuchenbaecker KB, McGuffog L, Barrowdale L, Lee A, Soucy P, Healey S, Dennis J, Lush M,
325 M, Spurdle AB, et al. Evaluation o 325 M, Spurdle AB, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction
326 in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst.* 2017; 109:djw302.
327 8. Stiller S, Drukewitz
-
- 325 M, Spurdle AB, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction
326 in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst.* 2017; 109:djw302.
327 S. Stiller S, Drukewitz 326 In BRCA1 and BRCA2 mutation carriers. J Nati-Cancer Inst. 2017, 109:djw302.
327 8. Stiller S, Drukewitz S, Lehmann K, Hentschel J, Strehlow V. Clinical impact of poly
328 breast cancer risk prediction in 382 individual 328 breast cancer risk prediction in 382 individuals with hereditary breast and ovarian cancer syndrome
329 *Cancers (Basel).* 2023; 15:3938.
330 9. Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, 329 breast cancer risk prediction in 382 individuals with hereditary breast and ovarian cancer syndrome.
330 330 329 Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, Roberts J, Ruston R, Walt
331 FM
- 329 Carver T, Hartley S, Lee A, Cunn
330 9. Carver T, Hartley S, Lee A, Cunn
331 FM, Tischkowitz M, et al. Can
832 risk and the likelihood of carryin
- 330 9. Carver T, Hartley S, Lee A, Cammignant Art, Archer S, Babb de Villiers C, Roberts S, Ruston R, Walter
331 FM, Tischkowitz M, et al. CanRisk tool a web interface for the prediction of breast and ovarian cance
332 r
-
-
- FM, Tischkowitz M, et al. CanRisk tool a web interface for the prediction of breast and ovarian cancer
332 Fisk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev.
333 2021; 30:4 333 risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemior Biomarkers Prev.
333 2021; 30:469–473.
334 10. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izq 333 2021, 30:469–473.

334 10. Lee A, Mavaddat N,

335 Simard J, Schmidt N

336 incorporating genet
-
- 335 Simard J, Schmidt MK, et al. BOADICEA: a comprehensive breast cancer risk prediction model
336 Simard J, Schmidt MK, et al. BOADICEA: a comprehensive breast cancer risk prediction model
336 Incorporating genetic and no
-
- 335 Simard J, Semmat MK, et al. BOADICEA: a comprehensive breast cancer risk prediction model
336 Simard J, Semmat MK, et al. BOADICEA: a comprehensive breast cancer risk prediction model
337 11. Carver T. Canrisk konwledg 11. Carver T. Canrisk konwledgebase. https://canrisk.atlassian.net/wiki/spaces/FAQS/
338 pages/35979266/What+variants+are+used+in+the+PRS, 2022. Accessed: 2022-11-3
339 12. Mavaddat N, Ficorella L, Carver T, Lee A, Cunning 337 11. Carver T. Canrisk konwiedgebase. https://canrisk.atlassian.net/wiki/spaces/FAQS/
338 pages/35979266/What+variants+are+used+in+the+PRS, 2022. Accessed: 2022-11
339 12. Mavaddat N, Ficorella L, Carver T, Lee A, Cunni
- 339 pages/35979266/What+variants+are+used+in+the+FRS, 2022. Accessed: 2022-11-50.
339 12. Mavaddat N, Ficorella L, Carver T, Lee A, Cunningham AP, Lush M, Dennis J, Tischkowitz
340 Hu D, et al. Incorporating Alternative Po
- 339 12. Mavaddat N, Ficorella L, Carver T, Lee A, Cunningham AP, Lush M, Dennis J, Tischkowitz M, Downes K,
340 Hu D, et al. Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk
15 340 Hu D, et al. Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk
15

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

-
- 341 Prediction Model. Cancer Epidemiol Biomarkers. 2023, 32:422–427.

342 B. Kiialainen A, Karlberg O, Ahlford A, Sigurdsson S, Lindblad-Toh K, Syv

343 microarray and liquid based capture methods for target enrichment for 342 13. Kiialainen A, Karlberg O, Ahlford A, Sigurdsson S, Endolad-Toh K, Syvänen AC. Periorinance of
343 microarray and liquid based capture methods for target enrichment for massively parallel sequend
344 SNP discovery.
-
- 343 microarray and niquid based capture methods for target ennement for massively parallel sequencing and
344 SNP discovery. *PLoS One.* 2011; 6:e16486.
345 14. Sulonen AM, Ellonen P, Almusa H, Lepistö M, Eldfors S, Hannul
- 345 SNP discovery. PLOS One. 2011, 0.e16486.
345 14. Sulonen AM, Ellonen P, Almusa H, Lepistö
346 P, Heckman C, et al. Comparison of solution
347 sequencing. *Genome Biol.* 2011; 12:1–18.
-
- 345 14. Sulonen AM, Enonen T, Annusa H, Lepisto M, Eldfors S, Hannula S, Miettinen T, Tyynismaa H, Salo
346 P, Heckman C, et al. Comparison of solution-based exome capture methods for next generation
347 sequencing. *Genom* 347 Sequencing. *Genome Biol.* 2011; 12:1–18.
348 Sequencing. *Genome Biol.* 2011; 12:1–18.
348 IS. Teer JK, Bonnycastle LL, Chines PS, Hansen NF, Aoyama N, Swift AJ, Abaan HO, Albert TJ, Marguencine EH, Green ED, et al. S 347 sequencing. Genome Biol. 2011, 12:1–18.
348 15. Teer JK, Bonnycastle LL, Chines PS, Hansen
349 EH, Green ED, et al. Systematic compariso
350 parallel DNA sequencing. *Genome Res.* 20
-
-
- 349 15. Teer JK, Bonnycastle EL, Chines PS, Hansen NF, Aoyama N, Swift AJ, Abaan Ho, Albert TJ, Margulies
350 parallel DNA sequencing. *Genome Res.* 2010; 20:1420–1431.
351 16. Yi M, Zhao Y, Jia L, He M, Kebebew E, Stephen 249 EH, Green ED, et al. Systematic comparison of three genomic enrichment methods for massively
350 parallel DNA sequencing. Genome Res. 2010; 20:1420–1431.
351 16. Yi M, Zhao Y, Jia L, He M, Kebebew E, Stephens RM. Perfo 350 parallel DNA sequencing. Genome Res. 2010, 20:1420–1431.
351 16. Yi M, Zhao Y, Jia L, He M, Kebebew E, Stephens RM. Perform
352 with illumina exome sequencing data – an assessment using bo
353 sample-matched SNP array 351 16. 11 M, Zhao 1, Jia L, He M, Kebebew E, Stephens RM. Performance comparison of SNP detection tools
352 with illumina exome sequencing data – an assessment using both family pedigree information and
353 sample-matched 353 with indiffulne sequencing data – an assessment data good ranny pedigree information and
353 sample-matched SNP array data. Nucleic Acids Res. 2014; 42:e101–e101.
354 17. Li H. Toward better understanding of artifacts
-
- 353 Sample-matched SNP andy data. Nucleic Acids Res. 2014, 42:e101–e101.
354 17. Li H. Toward better understanding of artifacts in variant calling from high
355 Bioinformatics. 2014; 30:2843–2851.
356 18. Reis AL, Deveson
-
- 17. Li H. Toward better understanding of artifacts in variant calling from high-coverage samples.

355 Bioinformatics. 2014; 30:2843–2851.

356 18. Reis AL, Deveson IW, Madala BS, Wong T, Barker C, Xu J, Lennon N, Tong W, 355 Bionijormatics. 2014, 30:2843–2851.
356 18. Reis AL, Deveson IW, Madala BS, Wo
357 synthetic chromosome controls to eva
358 genome. *Genome Biol.* 2022; 23:1–24
-
-
- 356 13. Reis AL, Deveson IW, Madala BS, Wong T, Barker C, Xu J, Lennon N, Tong W, Mercer TR. Using
357 synthetic chromosome controls to evaluate the sequencing of difficult regions within the human
358 genome. *Genome Biol* 358 synthetic chromosome controls to evaluate the sequencing or unital regions within the human
358 genome. *Genome Biol.* 2022; 23:1–24.
359 19. Stoler N, Nekrutenko A. Sequencing error profiles of illumina sequencing ins 359 genome. Genome Brot. 2022, 23:1–24.
359 19. Stoler N, Nekrutenko A. Sequencing er
360 *Bioinform.* 2021; 3:lqab019.
361 20. Gudmundsson S, Singer-Berk M, Watts 359 13. Stoler N, Nekrutenko A. Sequencing error promes or illumina sequencing instruments. NAR Genomic
360 8 Bioinform. 2021; 3: Iqab019.
362 Aggregation Database Consortium, Rehm HL, MacArthur DG, O'Donnell-Luria A. Vari
-
- 361 Biomjorm. 2021, 3:1qab019.
361 20. Gudmundsson S, Singer-Berk
362 Aggregation Database Consort
363 using population databases: Lo 361 20. Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, Genome 363 and using population databases: Lessons from gnomAD. Hum Mutat. 2022; 43:1012–1030.
364 21. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna
365 A, Birnbaum DP, et al
- 363 using population databases: Lessons from gnomAD. Hum Mutat. 2022, 43:1012–1030.
364 21. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laric
365 A, Birnbaum DP, et al. The mutational c
- 365 21. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna
365 A, Birnbaum DP, et al. The mutational constraint spectrum quantified from variation in 141,456 α , Birnbaum Dr, et al. The mutational constraint spectrum quantified from variation in 141,456 $\frac{1}{2}$

367 humans. *Nuture. 2020*, 381:434–443.
367 22. Sherry ST, Ward MH, Kholodov M, Ba
368 database of genetic variation. *Nucleio*
369 23. Collins RL, Brand H, Karczewski KJ, Zł

-
- 367 22. Sherry St, Ward MH, Kholodov M, Baker J, Phan L, Smiglelski EM, Shockin K. dbSNP: the NCBI
368 database of genetic variation. *Nucleic Acids Res.* 2001; 29:308–311.
369 23. Collins RL, Brand H, Karczewski KJ, Zhao 369 database of genetic variation. Nucleic Acids Res. 2001, 29:308–311.
369 23. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, Kh
370 Wang H, et al. A structural variation reference for medical and po 370 23. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli Lc, Khera AV, Lowther C, Gauthier LD,
370 Wang H, et al. A structural variation reference for medical and population genetics. Nature. 2020;
371 581:
- 371 S81:444–451.
372 S81:444–451.
24. Adeyemo A, Balaconis MK, Darnes DR, Fatumo S, Moreno PG, Hodonsky CJ, Inouye M, Kanai M,
373 Kato K, Knoppers BM, et al. Responsible use of polygenic risk scores in the clinic: potenti 372 24. Adeyemo A, B
373 Kato K, Knoppen
374 risks and gaps. 24. Adeyemo A, Balaconis MK, Darnes DK, Fatumo 3, Moreno Pd, Hodonsky CJ, Inouye M, Kanai M,
373 Kato K, Knoppers BM, et al. Responsible use of polygenic risk scores in the clinic: potential benefits
374 risks and gaps. *N*

1373 Kato K, Knoppers BM, et al. Responsible use of polygenic risk scores in the clinic: potential benefits,

1374 Fisks and gaps. Nat Med. 2021; 27:1876–1884.

1375 Sugrue LP, Desikan RS. What are polygenic scores and why 374 risks and gaps. Nut Med. 2021, 27:1876–1884.
375 25. Sugrue LP, Desikan RS. What are polygenic score
376 321:1820–1821.

377

375 25. Sugrue Er, Desikan RS. What are polygenic scores and why are they important? JAMA. 2015,
376 321:1820–1821.
378 **Acknowledgements.** We thank the coordinator of the GC-HBOC, Rita K. Schmutzler, and all GC-H 376 321:1820–1821.
377
378 **Acknowledgements.**
379 center directors for thei 379 Conter directors for their support of the GC-HBOC Bioinformatics Working Group. Further, we thank Joe Der
380 for helpful comments.
381

```
17 
 379 center directors for their support of the GC-HBOC Bioinformatics Working Group. Further, we thank Joe Dennis<br>380 for helpful comments.<br>382 The Bioinformatics Working Group of the German Consortium for Hereditary Breast
381<br>382 The Bioinformatics Wo<br>383 Norbert Arnold<sup>13</sup>, Alexa
382 The Bioinformatics Working Group of the German Consortium for Hereditary Breast & Ovarian Cancer. 
Norbert Arnold<sup>13</sup>, Alexandra Baumann<sup>14</sup>, Marvin Döbel<sup>15</sup>, Stephan Drukewitz<sup>16</sup>, Christoph Engel<sup>17</sup>, Corinna<br>
1884 Ernst<sup>18</sup>, Rudel Christian Nkouamedjo Fankep<sup>18</sup>, Michael Forster<sup>13</sup>, Peter Frommolt<sup>19</sup>, Eva Groß<sup>20</sup>
Ernst<sup>48</sup>, Rudel Christian Nkouamedjo Fankep<sup>48</sup>, Michael Forster<sup>49</sup>, Peter Frommolt<sup>49</sup>, Eva Groß<sup>48</sup>, Karl<br>1885      Hackmann<sup>14</sup>, Johannes Helmuth<sup>21</sup>, Ellen Honisch<sup>22</sup>, Tim Hutschenreiter<sup>14</sup>, Anna-Lena Katzke<sup>23</sup>, A
 Hackmann<sup>47</sup>, Johannes Helmuth<sup>44</sup>, Ellen Honisch<sup>44</sup>, Tim Hutschenreiter<sup>44</sup>, Anna-Lena Katzke<sup>46</sup>, Anna-Lena Kobiela<sup>18</sup>, Zarah Kowalzyk<sup>14</sup>, Oliver Kutz<sup>14</sup>, Christoph Meier<sup>24,25</sup>, Maximilian Radtke<sup>16</sup>, Juliane<br>1887 -
Lena Kobiela<sup>26</sup>, Zarah Kowalzyk<sup>24</sup>, Oliver Kutz<sup>24</sup>, Christoph Meier<sup>24,25</sup>, Maximilian Radtke<sup>26</sup>, Juliane<br>1887 - Ramser<sup>26</sup>, Robert Remy<sup>18</sup>, Julia Ritter<sup>21</sup>, Christian Ruckert<sup>27</sup>, Gunnar Schmidt<sup>23</sup>, Benedikt Schnur
 Ramser<sup>26</sup>, Robert Remy<sup>46</sup>, Julia Ritter<sup>24</sup>, Christian Ruckert<sup>27</sup>, Gunnar Schmidt<sup>23</sup>, Benedikt Schnur<sup>29</sup>, Dariush<br>1888 Skowronek<sup>28</sup>, Marc Sturm<sup>15</sup>, Katharina Thiedig<sup>26</sup>, Steffen Uebe<sup>29</sup>, Shan Wang-Gohrke<sup>30</sup>, Andr
Skowronek<sup>26</sup>, Marc Sturm<sup>25</sup>, Katharina Thiedig<sup>26</sup>, Steffen Uebe<sup>25</sup>, Shan Wang-Gohrke<sup>30</sup>, Andreas Zimmer<sup>22</sup><br>389 <sup>13</sup>Department of Gynecology and Obstetrics, Institute of Clinical Chemistry Institute of Clinical Molecu
<sup>13</sup> Department of Gynecology and Obstetrics, Institute of Clinical Chemistry Institute of Clinical Molecular<br>1390 Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. <sup>14</sup>Institute for Clinical Gen
Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. 14 390 Institute for Clinical Genetics,
```
It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

391 University Hospital Carl Gustav Carlos at TU Dresden, Dresden, Germany, ENN GENTUNIS, Hereditary
392 Cancer Syndrome Center Dresden, Germany; National Center for Tumor Diseases Dresden (NCT/UCC),
393 Germany: German Ca S92 Cancer Syndrome Center Dresden, Germany, National Center for Tumor Diseases Dresden (NCT/OCC),
393 Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and
394 University Hospital Car 393 Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and
394 University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany; German Cancer Consortium
395 (DKTK), Dresden, Germa University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany; German Cancer Consortium

(DKTK), Dresden, Germany; German Cancer Re- search Center (DKFZ), Heidelberg, Germany; Max Planck

Institute of Molecular Cel 395 (DKTK), Dresden, Germany, German Cancer Re- search Center (DKTZ), Heidelberg, Germany, Max Planck
396 Institute of Molecular Cell Biology and Genetics, Dresden, Germany. ¹⁵Institute of Medical Genetics and
398 Univer Institute of Molecular Cell Biology and Genetics, Dresden, Germany. ²⁵Institute of Medical Genetics and
1997 Applied Genomics, University Hospital Tübingen, Tübingen, Germany. ¹⁶Institute of Human Genetics,
1998 Univer Applied Genomics, University Hospital Tübingen, Tübingen, Germany. ²⁰Institute of Human Genetics,
398 University of Leipzig Medical Center, Leipzig, Germany. ¹⁷Institute for Medical Informatics, Statistics and
599 Epid University of Leipzig Medical Center, Leipzig, Germany. ¹⁷Institute for Medical Informatics, Statistics and

Epidemiology, University of Leipzig, Leipzig, Germany. ¹⁸Center for Familial Breast and Ovarian Cancer,

Cent Epidemiology (CIO), Medical Faculty, University of Cologne and University Hospital

401 Cologne, Cologne, Germany. ¹⁹ Institute for Human Genetics, University Hospital Hamburg-Eppendorf,

402 Hamburg, Germany. ²⁰ Depar Cologne, Cologne, Germany. ¹⁹Institute for Human Genetics, University Hospital Hamburg-Eppendorf,
402 Hamburg, Germany. ²⁰Department of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich,
403 Munich, Ge Cologne, Cologne, Germany. ²⁰ Institute for Human Genetics, University Hospital Hamburg-Eppendorf,
102 Hamburg, Germany. ²⁰ Department of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich,
103 Munich, Hamburg, Germany. ²⁰ Department of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich,
403 Munich, Germany. ²² Department of Human Genetics, Labor Berlin – Charité Vivantes GmbH, Berlin,
404 Germany. ² Munich, Germany. ²²Department of Human Genetics, Labor Berlin – Charité Vivantes GmbH, Berlin,
404 Germany. ²²Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine
405 University Düss Germany. ²² Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine
405 University Düsseldorf, Düsseldorf, Germany. ²³ Department of Human Genetics, Hannover Medical School
406 (MHH), H University Düsseldorf, Düsseldorf, Germany. "Department of Human Genetics, Hannover Medical School
406 (MHH), Hannover, Germany. ²⁴Institute of Human Genetics, University of Regensburg, Regensburg,
407 Germany. ²⁵Insti (MHH), Hannover, Germany. ²⁴ Institute of Human Genetics, University of Regensburg, Regensburg,

407 Germany. ²⁵ Institute of Clinical Human Genetics, University Hospital Regensburg, Regensburg, Germany.

408 ²⁶ Div 409 München, Germany. ²⁷Institute of Human Genetics, University of Münster, Münster, Germany. ²⁸Department
410 of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional ²⁶ 20 408 ²⁶ Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München,
26 München, Germany. ²⁷ Institute of Human Genetics, University of Münster, Münster, Germany. ²⁸ De München, Germany. ²⁷Institute of Human Genetics, University of Münster, Münster, Germany. ²⁹Department
10 of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional
11 Genom 411 Genomics, University of Greifswald, Greifswald, Germany. ²⁹Institute of Human Genetics,
412 Universitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Germany.
³⁰Department of Gynaecology an 411 Genomics, University of Greifswald, Greifswald, Germany. ²⁹Institute of Human Genetics,
412 Universitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Germany.
³⁰Department of Gynaecology an ³⁰Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.³¹Institute for Human
414 Genetics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg,
415 Ge 3030 ³⁰Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany. ³⁴Institute for Human
414 Genetics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg,
 414 Genetics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Frei 415 Germany.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.15.23298835;](https://doi.org/10.1101/2023.12.15.23298835) this version posted December 17, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.15.23298835;](https://doi.org/10.1101/2023.12.15.23298835) this version posted December 17, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

435 Figure legends

450 loci rs73754909 and rs79461387 (hg19-based). Both alternative alleles are deletions with the adjacent
451 downstream nucleotide identical to the expected substituted one.
452 451 downstream nucleotide identical to the expected substituted one.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

453 Table legends

-
- 454 Trable 1: Characteristics of data sets provided by participating centers of the German Consortium for
455 Hereditary Breast & Ovarian Cancer (GC-HBOC), namely the Institute of Medical Genetics and Applied
456 Genomics
-
-
- Genomics (IMGAG), University Hospital Tübingen, the Institute for Clinical Genetics (ICG), University H
457 Carl Gustav Carus Dresden, the Institute of Human Genetics at the University of Münster (IHG-M), the
458 for Famil 456 Genomics (IMGAG), University Hospital Tubingen, the Institute for Clinical Genetics (ICG), University Hospital
458 for Familial Breast and Ovarian Cancer (CFBOC), University Hospital Cologne, and the Institute of Human 457 Carl Gustav Carus Dresden, the Institute of Human Genetics at the University of Münster (IHG-M), the Center
458 for Familial Breast and Ovarian Cancer (CFBOC), University Hospital Cologne, and the Institute of Human
45
- 458 for Familian Breast and Ovarian Cancer (CFBOC), University Hospital Cologne, and the Institute of Human
459 Genetics at the University of Regensburg (IHG-R). Each center provided two data sets. BC/OC: Breast/ovaria
460
-

461

denetics at the University of Regensburg (IHG-R). Each center provided two data sets. BC/OC: Breast/ovariant
260 cancer; DP: Sequencing depth; PRS: Polygenic risk score.
261 able 2: Characteristics of loci incorporated in

460 cancer; DP: Sequencing depth; PRS: Polygenic risk score.
461 Table 2: Characteristics of loci incorporated in the BCAC 3
463 either not included in the gnomAD v3.1.2 database or rep

463 either not included in the gnomAD v3.1.2 database or reported with extremely deviating allele frequency
464 compared to CanRisk. Log odds ratios (ORs) are identical for BCAC 313 and BRIDGES 306, but missing value
465 i either not included in the gnomAD v3.1.2 database or reported with extremely deviating allele requency
464 compared to CanRisk. Log odds ratios (ORs) are identical for BCAC 313 and BRIDGES 306, but missing valu-
465 indica

- 464 compared to cannomic Log odds ratios (ORS) are identical for BCRC 313 and BRIDGES 300, but missing values
466 indicate loci not included in the corresponding PRS. Entries in the Comment column refer to technical artifa Franciate loci not included in the corresponding PRS. Entries in the comment column refer to technical artifacts
466 reported in gnomAD. LCR: low complexity region; LQS: low-quality site (in <50% of samples covered); VQSR:
-

468

467 failed allele-specific GATK Variant Quality Score Recalibration (VQSR) filter.
468 failed allele-specific GATK Variant Quality Score Recalibration (VQSR) filter.
469 fable 3: Summary of polygenic risk score genotyping 468
468 Fable 3: Summary of polygenic risk score genotyping results with noticeably
470 Fable 3: Summary of polygenic risk score genotyping results with noticeably
470 Fable 3: Summary of polygenic risk score genotyping re 470 of centers of the German Consortium for Hereditary Breast and Ovarian Cancer. Noticeably deviating AFs are
471 shown in bold. Loci (hg19-based) of rs11268668 and rs57589542 are 1-204502514-T-TTCTGAAACAGGG (hg19)
472 an 470 of centers of the German Consortium for Hereditary Breast and Ovarian Cancer. Noticeably deviating AFs are
471 shown in bold. Loci (hg19-based) of rs11268668 and rs57589542 are 1-204502514-T-TTCTGAAACAGGG (hg19
473 and 471 shown in bold. Loci (hg19-based) of rs11268668 and rs57585542 are 1-204502514-T-TTCTGAAACAGGG (hg19)
and 6-152022664-CAAAAAAA-C (hg19), respectively. WGS: Whole-genome sequencing. MGP: Multi-gene
panel sequencing. FB: and 6-152022664-CAAAAAA-C (hg19), respectively. WGS: Whole-genome sequencing. MGP: Multi-gene

473 panel sequencing. FB: freebayes.

474 Table 4: Potential solutions for improving polygenic risk score (PRS) genotyping perf

474

473 panel sequencing. FB: Heebayes.
474
475 Table 4: Potential solutions for im
476 the achievement of allele frequer 475 Table 4: Fotential solutions for improving polygenic risk score (PRS) genotyping performance with respect to
476 the achievement of allele frequencies (AFs) expected by CanRisk, using alternative alleles or proxys. Re 476 the achievement of allele frequencies (AFs) expected by CanRisk, using alternative alleles or proxys. Resulting
477 AFs were investigated based on gnomAD v3.1.2 non-Finnish European data and genotyping results of 1410 477 AFs were investigated based on gnomAD v3.1.2 non-Finnish European data and genotyping results of 1410

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.15.23298835;](https://doi.org/10.1101/2023.12.15.23298835) this version posted December 17, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

-
- 479 European whole-genome sequencing (WGS) samples using (unforced) freebayes, provided by the institute of
479 Medical Genetics and Applied Genomics (IMGAG) at University Hospital Tübingen. 479 Medical Genetics and Applied Genomics (IMGAG) at University Hospital Tübingen.

rs73754909 (hg19: 6-87803819-T-C)

rs79461387 (hg19: 17-29168077-G-T)

*6-87094100-CAGAAACTTTAAAAGATTCCTTTT-C (hg19)

†10-71335572-TCC-T (hg19)

‡17-29168076-AGAG-A (hg19)